Product Datasheet

Valiltramiprosate


Catalog No. **BP-01831** · CAS **1034190-08-3** · Form **free base** · Physical state **solid** · Color **white to off-white** · Version **1.0** · Revision **2026-11-04**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
Amyloid-β	**Neurological Disease**

Molecular formula	**$C_8H_{18}N_2O_4S$**
Molecular weight	**238.3050**

STRUCTURE



DESCRIPTION

ALZ-801 is a potent and orally available small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor, valine-conjugated proagent of Tramiprosate with substantially improved PK properties and gastrointestinal tolerability compared with the parent compound. ALZ-801 is an advanced and markedly improved candidate for the treatment of alzheimer's disease.

BIOLOGICAL ACTIVITY

ALZ-801 (oral administration; 172?mg/kg; single dose) exhibits mean AUCt values of 58,758 and? 5841 ng/ml.h in plasma and brain, respectively. The ALZ-801: Tramiprosate ratio in plasma and brain is 1.8 and 3.1, respectively in male CD-1 mice

SOLUBILITY

Soluble in H2O : 30 mg/mL

REFERENCES

[1]. John A. Hey, et al. Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain. CNS Drugs. 2018; 32(9): 849–861.

[2]. Hey JA, et al. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease. Clin Pharmacokinet. 2018 Mar;57(3):315-333.